Periodicidad semestral: flujo continuo.
ISSN - Electrónico: 2661-6947 / DOI: 10.36015 • LILACS BIREME (19784); LATINDEX (20666)
INTRODUCTION: BK polyomavirus nephropathy is emerging as a significant concern in kidney transplantation, as it contributes to the early loss of renal grafts. OBJECTIVE: The aim of this study was to clinically characterize renal transplant recipients with BK polyomavirus nephropathy. MATERIALS AND METHODS: An observational and descriptive study was conducted at Carlos Andrade Marín Specialties Hospital during the period of 2013 to 2022. An anonymized database comprising 479 renal transplant
patients was utilized. Among these, 37 patients, constituting 7.7%, were identified with BK polyomavirus nephropathy. Data analysis was performed using the statistical program SPSS v26®. RESULTS: The study population was predominantly composed of male patients (56.8%) with a mean age of 48.2 years. Deceased donors accounted for the majority (94.5%) of cases. The primary approach for managing BK polyomavirus
nephropathy involved transitioning from mycophenolate sodium to everolimus, alongside maintaining a regimen of 50% tacrolimus and 40.5% prednisone. When assessing changes in creatinine values, the highest levels were observed at 12 months, coinciding with early renal loss (p: 0.042). Similarly, at the 12-month mark, elevated creatinine levels were associated with a histopathological diagnosis of Polyomavirus
nephropathy Class 3 (p: 0.01). DISCUSSION: The prevalence of nephropathy remained below the globally reported threshold of 10%. Creatinine levels worsened in patients experiencing early graft loss and an advanced pathological classification, aligning with established disease pathophysiology. CONCLUSION: Early renal graft loss was associated with higher creatinine levels compared to delayed loss. Adequate
screening for early detection of BK virus is recommended, as it plays a crucial role in preventing renal function deterioration and limiting subsequent graft loss.
Saleh A, El Din Khedr M, Ezzat A, Takou A, Halawa A. Update on the Management of BK Virus Infection. Exp
Clin Transplant. 2020; 18(6):659-70. DOI: https://doi.org/10.6002/ect.2019.0254. Available from:
https://www.ectrx.org/detail/archive/2020/18/6/0/659/0
Ortiz L, Rosado L, Ceballos G, Salcedo M, Pool M. Enfermedad renal crónica y factores de supervivencia en pacientes con trasplante renal: revisión de la literatura. Revista Salud y Bienestar social. 2021; 5(1): 41-58. Disponible en:
https://www.revista.enfermeria.uady.mx/ojs/index.php/Salud/article/view/91
Breyer I, Parajuli S. Retransplantation After Kidney Graft Failure Due to BK Polyomavirus Nephropathy. Complications in Kidney Transplantation: A Case-Based Guide to Management. Complications in Kidney Transplantation. 2022: 433-436. DOI: https://doi.org/10.1007/978-3-031-13569-9_67. Disponible en: https://link.springer.com/chapter/10.1007/978-3-031-13569-9_67
Sánchez A. Infección por virus BK en el trasplante renal: actualización. Nefrología. 2018; 9: 17-27. Disponible en:
https://www.revistanefrologia.com/es-infeccion-por-virus-bk-el-articulo-X2013757518630876
Kotla SK, Kadambi PV, Hendricks AR, Rojas R. BK polyomavirus— pathogen, paradigm and puzzle. Nephrol
Dial Transplant. 2021; 36(4):587-593. DOI: https://doi.org/10.1093/ndt/gfz273. Available from:
https://academic.oup.com/ndt/article/36/4/587/5692242
Rodríguez-Benot A, Suarez-Fernández ML, Fernández-Tagarro E, Cañas L, Calvo-Romero N, Amenábar J. Nefropatía por poliomavirus BK. Diagnóstico y tratamiento. Nefrología. 2018;9(Suppl 2): S50-S66. Disponible en: https://www.revistanefrologia.com/index.php?p=revista&tipo=pdf-simple&pii=X2013757518630907&r=100
Karimi L, Makvandi M, Timori A. Prevalence of Human Polyomavirus JC and BK in Normal Population. Asian
Pac J Cancer Prev. 2020; 21(10):2877-82. DOI:
https://doi.org/10.31557/apjcp.2020.21.10.2877. Available from:
https://pubmed.ncbi.nlm.nih.gov/33112543/
Chong S, Antoni M, Macdonald A, Reeves M, Harber M, Magee CN. BK virus: Current understanding of pathogenicity and clinical disease in transplantation. Rev Med Virol. 2019;29(4): e2044. DOI: https://doi.org/10.1002/rmv.2044. Available from:
https://onlinelibrary.wiley.com/doi/10.1002/rmv.2044
Sharma R, Mareena Z. BK virus nephropathy: prevalence,impact and management strategies. International Journal of Nephrology and Renovascular Disease. 2020; (13):187-192. DOI: https://doi.org/10.2147%2FIJNRD.S236556. Available from:
https://www.dovepress.com/bk-virus-nephropathy-prevalence-impact-and-management-strategies-
peer-reviewed-fulltext-article-IJNRD
Santana C, Gallego R, Pena M, Camacho R, Santana R, Aladro S, et al. Nefropatía por poliomavirus JC en paciente trasplantado renal, un invitado infrecuente. Nefrología. DOI: https://dx.doi.org/10.1016/j.nefro.2023.02.001. Available from:
https://www.sciencedirect.com/science/article/pii/S0211699523000279?via%3Dihub
Alcendor DJ. BK Polyomavirus Virus Glomerular Tropism: Implications for Virus Reactivation from Latency
and Amplification during Immunosuppression. J Clin Med. 2019; 8(9):1477. DOI: https://doi.org/10.3390%-
Fjcm8091477. Available from:
https://pubmed.ncbi.nlm.nih.gov/31533282/
Favi E, Puliatti C, Sivaprakasam R, Ferraresso M, Ambrogi F, Delbue S, et al. Incidence, risk factors, and outcome of BK polyomavirus infection after kidney transplantation. World J Clin Cases. 2019;7(3): 270-290. DOI: https://doi.org/10.12998%2Fwjcc.v7.i3.270. Available from:
https://www.wjgnet.com/2307-8960/full/v7/i3/270.htm
Krejci K, Tichy T, Bednarikova J, Zamboch K, Zadrazil J. BK virus-induced renal allograft nephropathy.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162(3):165-177. DOI: https://doi.org/10.5507/
bp.2018.018. Available from:
Nickeleit V., Singh H.K., Randhawa P., Drachenberg C.B., Bhatnagar R., Bracamonte E., Chang A., Chon
W.J., Dadhania D., Davis V.G., et al. The Banff Working Group Classification of Definitive Polyomavirus Nephropathy: Morphologic Definitions and Clinical Correlations. J. Am. Soc. Nephrol. 2018;29:680–693. DOI: 10.1681/ASN.2017050477. Available from:
https://www.google.com/search?client=firefox-b-d&q=doi%3A+10.1681%-2FASN.2017050477
Vincenti F, Cruzado J, Mulgaonkar S, Garcia V, Kuypers D, Buchler M, Citterio F, Huynh-Do U, Luo WL, Bernhardt P, Sommerer C. The TRANSFORM study: Infection outcomes with everolimus plus reduced calcineurin inhibitor and mycophenolate plus standard calcineurin inhibitor regimens in DE Novo kidney transplant recipients. American Transplant Congress; 2018; 3. Disponible en:
Kant S, Dasgupta A, Bagnasco S, Brennan DC. BK Virus Nephropathy in Kidney Transplantation: A State-ofthe-Art Review. Viruses. 2022; 14(8):1616. DOI: https://doi.org/10.3390/v14081616. Available from: https://www.mdpi.com/1999-4915/14/8/1616
Cohen-Bucay A, Ramirez-Andrade SE, Gordon CE, Francis JM, Chitalia VC. Advances in BK Virus Complications
in Organ Transplantation and Beyond. Kidney Med. 2020;2(6):771-786. DOI: https://doi.org/10.1016/j.
xkme.2020.06.015. Available from:
https://www.kidneymedicinejournal.org/article/S2590-0595(20)30205-3/fulltext
Van Doesum W, Gard L, Bemelman F, De Fijter, Homan J, Niesters H, et al. Incidence and outcome of BK polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporine‐,mycophenolate sodium‐, or everolimus‐based low‐dose immunosuppressive therapy. Transplant Infectious Disease. 2017; 19(3): e12687. DOI:
https://doi.org/10.1111/tid.12687
Imlay H, Whitaker K, Fisher CE, Limaye AP. Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis. 2018;20(4): e12928. DOI: https://doi.org/10.1111/tid.12928
Sanders ML, Swee M, Fraer M, Kuppachi S, Ten Eyck P, Rastogi P. BK virus histopathologic disease severity does not predict allograft outcome in renal transplant recipients. Annals of Diagnostic Pathology. 2019; 42:1-6. DOI: https://doi.org/10.1016/j.anndiagpath.2019.06.012. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1092913419301595?via%3Dihub
Zakaria E, et al. Screening for BK viremia/viruria and the impact of management of BK virus nephropathy in
renal transplant recipients. Exp Clin Transplant. 2019; 17, no Suppl 1: 83-91. DOI: https://doi.org/10.6002/ect.
mesot2018.o17. Available from:
The authors who publish in this journal accept the following conditions:
1. The authors retain the copyright and grant to the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM the right of the first publication, with the work registered with the Creative Commons attribution license, which allows third parties to use the published material provided that they mention the authorship of the work and the first publication in this journal.
2. Authors can make other independent and additional contractual agreements for the non-exclusive distribution of the version of the article published in this journal (for example, include it in an institutional repository or publish it in a book) as long as it clearly indicates that the work was published. for the first time in the CAMbios MEDICAL-SCIENTIFIC JOURNAL HECAM.
